Healthcare Industry News: Lipsovir
News Release - September 6, 2007
Medivir Reinforces Management Group
STOCKHOLM, Sweden--(HSMN NewsFeed)--Regulatory News: Stefan Martensson has been appointed Vice President Sales & Marketing, a newly created position with responsibility for the establishment and operation of Medivir's (STO:MVIRB) future regional sales and marketing organization. He commences in October 2007 and will belong to the Medivir management team. Medivir presently has one project in phase III clinical trials (Lipsovir®), three projects in phase II and three in phase I. Medivir has operational responsibility for two of these projects - Lipsovir® and MIV-701 - while collaborating partners are responsible for the others. Medivir has retained the regional marketing rights for all of these projects. Existing and future collaboration agreements with other companies can provide additional opportunities for sales and marketing of further pharmaceuticals in the regional market. Stefan Martensson has a masters degree in economics and has had senior positions within marketing, sales and business development with global pharmaceutical companies such as GlaxoSmithKline and Novartis over the last 20 years. Stefan comes most recently from a position as Head of Marketing at Novartis Sverige AB. "Stefan's long experience of the Nordic pharmaceutical markets and his widespread contact net within the global pharmaceutical industry will make him extremely valuable in the task of building and operating Medivir's future sales and marketing organization", says Medivir's CEO Lars Adlersson.For further information on Medivir, please see our website: www.medivir.se
Source: Medivir
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
